The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1155
April 28, 2003
View Complete Issue         Table of Contents 2019 
Eletriptan (Relpax) for Migraine
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Eletriptan (Relpax) for Migraine
April 28, 2003 (Issue: 1155)
Eletriptan hydrobromide (Relpax Pfizer) is now available in the US for oral treatment of migraine headache in adults. It is the seventh serotonin 5-HT1B/1D-receptor agonist (triptan) to be approved by the FDA for this indication. This review...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Eletriptan (Relpax) for Migraine
Article code: 1155a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.